IL-17A

Rat

E.coli

CTLA8; CTLA-8

Interleukin-17A (IL-17A), also known as CTLA-8, is a glycosylated cytokine that plays an important role in anti-microbial and chronic inflammation. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold. Mature rat IL-17A shares 60% and 89% amino acid sequence identity with human and mouse IL-17A, respectively. IL-17A is secreted by Th17 cells, gamma /δ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells. It forms disulfide-linked homodimers as well as disulfide-linked heterodimers with IL-17F. IL-17A exerts its effects through the transmembrane IL-17RA in complex with IL-17RC or IL-17RD. Both IL-17RA and IL-17RC are required for responsiveness to heterodimeric IL-17A/F. IL-17A promotes protective mucosal and epidermal inflammation in response to microbial infection. It induces chemokine production, neutrophil influx, and the production of antibacterial peptides. IL-17A/F likewise induces neutrophil migration, but IL-17F does not. IL-17A additionally enhances the production of inflammatory mediators by rheumatoid synovial fibroblasts and contributes to TNF-alpha induced shock. In contrast, it can protect against the progression of colitis by limiting chronic inflammation. IL-17A encourages the formation of autoreactive germinal centers and exacerbates the onset and progression of experimental models of autoimmunity. IL-17A has been shown to exert either tumorigenic or anti-tumor effects.

Approximately 30.0 kDa.

AVLIPQSSVC PNAEANNFLQ NVKVNLKVIN SLSSKASSRR PSDYLNRSTS PWTLSRNEDP DRYPSVIWEA QCRHQRCVNA EGKLDHHMNS VLIQQEILVL KREPEKCPFT FRVEKMLVGV GCTCVSSIVR HAS

Sterile Filtered White lyophilized (freeze-dried) powder.

> 95% by SDS-PAGE and HPLC analyses.

The ED50 as determined by inducing IL-6 secretion of murine NIH/3T3 cells is less than 1.0 ng/mL, corresponding to a specific activity of > 1.0 × 106 IU/mg. Fully biologically active when compared to standard.

< 0.1 EU per 1μg of the protein by the LAL method.

Lyophilized from a 0.2 µm filtered concentrated solution in 2 × PBS, pH 6.5.

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.

5, 100, 500μg